Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer

• Published in: PloS one 2015-07, Vol.10 (7), p.e0131889-e0131889
• Main Authors: Andersson, Elin, Dahmcke, Christina M, Steven, Kenneth, Larsen, Louise K, Guldberg, Per
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - urine; Bladder; Bladder cancer; Cancer; Cancer diagnosis; Cancer genetics; Cell Line, Tumor; Cell Separation - instrumentation; Cell Separation - methods; Cellular biology; Collection; Cystoscopy; Demography; Deoxyribonucleic acid; Diagnostic systems; DNA; DNA - urine; DNA Methylation; DNA Mutational Analysis; FDA approval; Female; Fibroblast growth factor receptors; Filtration; Filtration - instrumentation; Histopathology; Housing; Humans; Kinases; Male; Markers; Medical diagnosis; Methylation; Middle Aged; Mutation; Patients; Point-of-Care Systems; Polymorphism, Single Nucleotide; Pore size; Preservation; Receptor, Fibroblast Growth Factor, Type 3 - genetics; Ships; Specimen Handling - instrumentation; Specimen Handling - methods; Storage; Tumors; Urinary bladder; Urinary Bladder Neoplasms - diagnosis; Urinary Bladder Neoplasms - metabolism; Urinary Bladder Neoplasms - pathology; Urine
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0131889

Molecular analysis of cells from urine provides a convenient approach to non-invasive detection of bladder cancer. The practical use of urinary cell-based tests is often hampered by difficulties in handling and analyzing large sample volumes, the need for rapid sample processing to avoid degradation of cellular content, and low sensitivity due to a high background of normal cells. We present a filtration device, designed for home or point-of-care use, which enables collection, storage and shipment of urinary cells. A special feature of this device is a removable cartridge housing a membrane filter, which after filtration of urine can be transferred to a storage unit containing an appropriate preserving solution. In spiking experiments, the use of this device provided efficient recovery of bladder cancer cells with elimination of >99% of excess smaller-sized cells. The performance of the device was further evaluated by DNA-based analysis of urinary cells collected from 57 patients subjected to transurethral resection following flexible cystoscopy indicating the presence of a tumor. All samples were tested for FGFR3 mutations and seven DNA methylation markers (BCL2, CCNA1, EOMES, HOXA9, POU4F2, SALL3 and VIM). In the group of patients where a transitional cell tumor was confirmed at histopathological evaluation, urine DNA was positive for one or more markers in 29 out of 31 cases (94%), including 19 with FGFR3 mutation (61%). In the group of patients with benign histopathology, urine DNA was positive for methylation markers in 13 out of 26 cases (50%). Only one patient in this group was positive for a FGFR3 mutation. This patient had a stage Ta tumor resected 6 months later. The ability to easily collect, store and ship diagnostic cells from urine using the presented device may facilitate non-invasive testing for bladder cancer.